Could a diabetes drug ease long COVID fatigue?
NCT ID NCT07128082
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether tirzepatide (Zepbound), a drug used for diabetes and weight loss, can reduce Long COVID symptoms like fatigue. About 1000 adults with Long COVID will take either the drug or a placebo for 12 months, and all tasks are done remotely. The main goal is to see if fatigue scores improve compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tirzepatide (Zepbound)
- What this could lead to
- If it works, this could point toward a treatment that reduces fatigue and improves quality of life for people with Long COVID.
- What could go wrong
- This is a Phase 2 trial, so it is still early. The medication may not work better than a placebo, and side effects from tirzepatide (like nausea or digestive issues) are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scripps Research
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Can brain training zap long COVID brain fog?
- Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog
- Smartphone therapy could ease long COVID's mental toll